1100 13th Street, NW, Suite 750Washington, DC 20005202.887.6400Toll-free: 800.544.0155
All Contents © 2018The Kiplinger Washington Editors
Most people may not know it, but only a handful out of every thousand drugs that begin development ever make it to the final stages of trials – and not all of those are approved.
This maker of generic drugs is priced as if it were a fading company. The facts show otherwise.
Fairholme, a superb fund, is shifting out of commodities and into drug stocks and managed-care companies. The timing looks perfect.
More Investing News »